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 in 1994 by Breaker and Joyce (3)
 trans esterification reaction (3)
















 DNAzymes are catalytically active DNA molecules(6)
 their capability to cleave RNA molecules (6)












The latter is composed of 15 deoxynucleotide






 half life from 70 min to 21 h in human serum (2)




 DNAzymes represent a particular class of antisense
molecule(4)




Main   Applications
 also used as active components for constructing
nanostructures (3)
 important functional nucleic acids for chemical biology
medicine, analytical chemistry and materials science. (3)
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 lead to down-regulation of protein expression(5)
 their use as amplifying labels for the development
of optical or electronic sensors(3)
Main   Applications
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advantages as compared to enzymes 
1. In contrast to enzymes that are thermally unstable(8)
2. impressively stable under ambient and even elevated
temperatures(8)






1. drug delivery systems (DDSs)
2. DNAzyme-based biosensors and nanodevices







 recognition elements and promising signal amplifiers in biosensor (3)
 based on colorimetry, Surface Enhanced Raman Scattering(SERS),
fluorescence, or electrochemistry. (3)
 Broad range of cofactors: such as Pb2+,UO2+, Cu2+, Zn2+, and histidine (3)






To investigate whether the produced Mn2+ ions from the reduction of MnO2 nanosheets could act as cofactors
for 10–23 DNAzyme, the effect of Mn2+ on the catalytic activity of DNAzyme for RNA cleavage was analyzed by
agar electrophoresis. It can be seen in Figure 1 that 0.2 mm of Mn2+ ions could trigger 10–23 DNAzyme to
completelycleave the substrate within 60 min. However, under the same conditions, a concentration of 15 mm












 nanomaterial assisted like AuNPs, GO, CNT, QDs(9)
 provide novel sensing systems based on colorimetry,









Treatment the cancer”s and diseases(1)
Activity of DNAzymes against Cancer Cells 
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 inhibited proliferation and induced apoptosis (10)
 induce the release of cytochrome c from
mitochondria(10)
DNAzyme Delivery—Facing the Beast of a Challenge(10) 
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Drug Delivery Systems (DDSs)
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 presenting drug agents against cancer(5)
 target gene knockdown agents(5)
 more emphasis needs to be placed on actual efficacy and safety(5)
 chitosan and polyethylenimine (PEI)(8)
Drug Delivery Systems (DDSs)(3)
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DNAzymes – Short overview of in vitro usage.(5)
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mRNA target                Pathogenesis                                 DNAzyme usage
Bcr-abl Chronic myeloid leukaemia
(CML), acute lymphoblastic
leukaemia (ALL)
Three DNAzymes were designed against two variants of the 
p210 bcr-abl gene and p190 variant. DNAzymes were 
transfected into CML K562 cells using GS2888 cationic 
liposomal reagent.
β 1 and β 3 integrin Important in cell–cell and cell–
matrix
interactions in the pathogenesis of
various tumours.
Two DNAzymes to β 1 and β 3 mRNA were designed to 
contain a
15-deoxynucleotide catalytic domain fl anked by two substrate 
recognition segments of 8 and 10 deoxynucleotides
for β 1 and β 3 DNAzymes, respectively. DNAzymes were 
partially modifi ed with phosphorothioate and with 2’-O-




Receptor tyrosine kinase of the 
Erb B
receptor family that is abnormally
activated in epithelial tumours.
DNAzymes targeting the EGFR mRNA.




DNAzymes (Dz1 and Dz3) were designed to cleave the 
PML/RAR α transcript at the GC nucleotides at the fusion 
point and three nucleotide s upstream of that respectively.
Unique quadruple cleavage activity of designed DNAzymes.
DNAzymes – Short overview of in vivo usage(5)
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mRNA target                Pathogenesis                                 DNAzyme usage
Human survivin in 
PANC-1 cells
Human pancreatic carcinoma –
regulates cell division and 
inhibits apoptosis.
Anti-survivin mRNA DNAzyme designed.





Implicated in signal transduction 
and biological processes 




(Dz372, Dz483, Dz720) targeted
against three separate purine and







 pH values from 5 to 7(2)











Samples 0.5 h 1.0 h 2.0 h
Aqueous solut. 44 22 7
Acetate buffer 57 30 6
SME 25 10 2



























 easy to synthesize and functionalize(9)
 multiple enzymatic turnover properties(6)




 cleave an all-RNA(2)





 hairpins or aptamer–DNAzyme conjugates
 anticipated to appear on the market in the near future
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